BOSTON--(BUSINESS WIRE)--Novo Nordisk today announced the U.S. launch of the Wegovyâ"¢ pill, the first oral GLP-1 option approved by the Food and Drug Administration for chronic weight management. The introduction of an oral formulation marks a significant step forward in expanding patient choice, and access to evidence-based obesity treatment. The launch coincides with an expanded NovoCare® experience, designed to help patients find trusted care, understand coverage options, and access ongoing s. ...